MCID: CNN002
MIFTS: 44

Cannabis Abuse

Categories: Mental diseases

Aliases & Classifications for Cannabis Abuse

MalaCards integrated aliases for Cannabis Abuse:

Name: Cannabis Abuse 12 54 15 71
Marijuana Abuse 12 54 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9505
ICD9CM 34 305.2
MeSH 43 D002189
SNOMED-CT 67 37344009
ICD10 32 F12.1
UMLS 71 C0006868 C0024809

Summaries for Cannabis Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cannabis despite negative consequences.

MalaCards based summary : Cannabis Abuse, also known as marijuana abuse, is related to cyclic vomiting syndrome and polysubstance abuse. An important gene associated with Cannabis Abuse is CNR2 (Cannabinoid Receptor 2), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Topiramate and Buspirone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Cannabis Abuse

Diseases related to Cannabis Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 cyclic vomiting syndrome 30.4 OPRM1 CNR1
2 polysubstance abuse 29.9 FAAH DRD2 COMT CNR1
3 alexithymia 29.7 HTR1A DRD2 COMT
4 sleep disorder 29.5 HTR1A DRD2 BDNF
5 conduct disorder 29.5 GABRA2 DRD4 DRD2 COMT
6 withdrawal disorder 29.3 SPICE1 OPRM1 FAAH DRD2 CNR1
7 cannabis dependence 29.0 WASF1 NRG1 NAPEPLD MGLL GABRA2 FAAH
8 personality disorder 29.0 HTR1A DRD4 DRD2 COMT BDNF
9 drug dependence 29.0 OPRM1 GABRA2 DRD2 CNR1 BDNF
10 cocaine dependence 28.9 OPRM1 GABRA2 DRD2 COMT CNR1
11 antisocial personality disorder 28.9 WASF2 WASF1 GABRA2 DRD4 DRD2 COMT
12 mood disorder 28.7 HTR1A DRD4 DRD2 COMT BDNF
13 panic disorder 28.6 HTR1A DRD4 DRD2 COMT BDNF
14 attention deficit-hyperactivity disorder 28.0 OPRM1 NGF HTR1A DRD4 DRD2 COMT
15 psychotic disorder 27.9 OPRM1 NRG1 HTR1A DRD4 DRD2 COMT
16 substance dependence 27.9 WASF2 WASF1 OPRM1 GABRA2 DRD4 DRD2
17 alcohol use disorder 27.9 WASF2 WASF1 OPRM1 HTR1A GABRA2 DRD2
18 substance abuse 27.5 WASF2 WASF1 OPRM1 HTR1A GABRA2 DRD4
19 bipolar disorder 27.2 NRG1 NGF HTR1A GABRA2 DRD4 DRD2
20 anxiety 27.2 OPRM1 NGF HTR1A GABRA2 FAAH DRD4
21 alcohol dependence 27.0 OPRM1 NGF HTR1A GABRA2 FAAH DRD4
22 schizophrenia 26.5 OPRM1 NRG1 NGF HTR1A GABRA2 FAAH
23 adrenal gland pheochromocytoma 10.5 NGF BDNF
24 lumbosacral plexus lesion 10.5 NGF BDNF
25 autoimmune encephalitis 10.5 FAAH CNR1
26 early-onset schizophrenia 10.4 DRD2 BDNF
27 histrionic personality disorder 10.4 WASF2 WASF1
28 narcissistic personality disorder 10.4 WASF2 WASF1
29 paranoid personality disorder 10.4 WASF2 WASF1
30 uvulitis 10.4 MGLL CNR1
31 barbiturate abuse 10.4 WASF2 WASF1
32 diabetic encephalopathy 10.3 NGF BDNF
33 obsessive-compulsive personality disorder 10.3 WASF2 WASF1
34 tardive dyskinesia 10.3 DRD2 COMT
35 tendinosis 10.3 CNR1 BDNF
36 chronic cystitis 10.3 NGF BDNF
37 autoimmune disease of central nervous system 10.3 NGF CNR1 BDNF
38 cocaine abuse 10.3 NGF DRD2 BDNF
39 traumatic brain injury 10.2 DRD2 COMT BDNF
40 brain injury 10.2 DRD2 COMT BDNF
41 toxic encephalopathy 10.2 NGF DRD2 BDNF
42 schizoid personality disorder 10.2 WASF2 WASF1 DRD2
43 ocular dominance 10.2 NGF BDNF
44 idiopathic corneal edema 10.2 DRD4 DRD2
45 amphetamine abuse 10.2 DRD4 CNR1
46 asperger syndrome 10.1 NGF COMT CNR1 BDNF
47 periodic limb movement disorder 10.1 DRD4 DRD2
48 paralytic ileus 10.1 OPRM1 CNR1
49 severe combined immunodeficiency 10.1
50 oculogyric crisis 10.1 DRD4 DRD2

Graphical network of the top 20 diseases related to Cannabis Abuse:



Diseases related to Cannabis Abuse

Symptoms & Phenotypes for Cannabis Abuse

MGI Mouse Phenotypes related to Cannabis Abuse:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 BDNF CNR1 COMT DRD2 DRD4 FAAH
2 behavior/neurological MP:0005386 10.1 BDNF CNR1 COMT DRD2 DRD4 FAAH
3 integument MP:0010771 9.81 BDNF CNR1 CNR2 DRD2 FAAH GABRA2
4 nervous system MP:0003631 9.8 BDNF CNR1 COMT DRD2 DRD4 FAAH
5 no phenotypic analysis MP:0003012 9.28 BDNF CNR1 DRD2 GABRA2 HTR1A MGLL

Drugs & Therapeutics for Cannabis Abuse

Drugs for Cannabis Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4 97240-79-4 5284627
2
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
3
Clozapine Approved Phase 4 5786-21-0 2818
4
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
5
Haloperidol Approved Phase 4 52-86-8 3559
6
Ondansetron Approved Phase 4 99614-02-5 4595
7 Anticonvulsants Phase 4
8 Hypoglycemic Agents Phase 4
9 Tranquilizing Agents Phase 4
10 Anti-Anxiety Agents Phase 4
11 Serotonin Receptor Agonists Phase 4
12 Serotonin Agents Phase 4
13 Antipsychotic Agents Phase 4
14 Serotonin Antagonists Phase 4
15 Antidepressive Agents Phase 4
16 Quetiapine Fumarate Phase 4 111974-72-2
17 Dopamine Antagonists Phase 4
18 Antiemetics Phase 4
19 Gastrointestinal Agents Phase 4
20 Cytochrome P-450 Enzyme Inhibitors Phase 4
21 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
22 Serotonin Uptake Inhibitors Phase 4
23 Dermatologic Agents Phase 4
24 Haloperidol decanoate Phase 4
25 Antipruritics Phase 4
26 Neurotransmitter Agents Phase 4
27 Atomoxetine Hydrochloride Phase 4
28 Adrenergic Agents Phase 4
29
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
30
Nabilone Approved, Investigational Phase 2, Phase 3 51022-71-0 5284592
31
Diphenhydramine Approved, Investigational Phase 2, Phase 3 147-24-0, 58-73-1 3100
32
Zolpidem Approved Phase 2, Phase 3 82626-48-0 5732
33
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
34
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
35
Lofexidine Approved, Investigational Phase 2, Phase 3 31036-80-3 30668
36
Peppermint oil Approved, Investigational Phase 3 8006-90-4
37
Peppermint Approved Phase 3
38
Nicotine Approved Phase 3 54-11-5 942 89594
39
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
40
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
41
Vortioxetine Approved, Investigational Phase 2, Phase 3 508233-74-7 9966051
42
Amphetamine Approved, Illicit, Investigational Phase 2, Phase 3 300-62-9 5826 3007
43
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
44
Dronabinol Approved, Illicit Phase 2, Phase 3 1972-08-3 16078
45
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
46
Cysteine Approved, Nutraceutical Phase 2, Phase 3 52-90-4 5862
47 Nabiximols Investigational Phase 3 56575-23-6
48
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
49 Antimanic Agents Phase 3
50 Hypnotics and Sedatives Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 325)
# Name Status NCT ID Phase Drugs
1 N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms Unknown status NCT03221231 Phase 4 N-acetylcysteine;Placebo Oral Tablet
2 Cannabis and Schizophrenia: Effects of Clozapine Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
3 Clozapine for Cannabis Use Disorder in Schizophrenia Completed NCT01639872 Phase 4 Clozapine;Risperidone
4 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
5 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo
6 Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial Completed NCT03056482 Phase 4 Ondansetron 8mg;Haloperidol 0.05mg/kg;Haloperidol 0.1mg/kg
7 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Completed NCT01153490 Phase 4
8 Nicotine for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
9 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
10 An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse. Terminated NCT00687609 Phase 4 Atomoxetine
11 Family and Group Therapies for Adolescent Alcohol Abuse Unknown status NCT00484367 Phase 2, Phase 3
12 Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II) Unknown status NCT00673647 Phase 3
13 Reducing Injury, ETOH and THC Use Among ED Patients Unknown status NCT00547963 Phase 2, Phase 3
14 A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal Completed NCT01025700 Phase 2, Phase 3 Cesemat
15 Reducing STIs in Emerging Adults Who Use Alcohol and Marijuana Completed NCT01473719 Phase 3
16 A Brief Marijuana Intervention for Adolescent Women Completed NCT00227864 Phase 3
17 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
18 Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents Completed NCT00218114 Phase 3 Divalproex Sodium;Placebo
19 Facilitating the Behavioral Treatment of Cannabis Use Disorder Completed NCT02946489 Phase 2, Phase 3 CI-581a
20 Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With Temporomandibular Disorders: a Randomized, Double-blind Study Completed NCT03994640 Phase 2, Phase 3
21 The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury Completed NCT01555983 Phase 2, Phase 3 Vaporization of Cannabis
22 A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence Completed NCT01020019 Phase 2, Phase 3 Dronabinol;Placebo;Lofexidine
23 Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) Completed NCT01675661 Phase 3 N-Acetylcysteine;Placebo
24 A Double Blind, Randomised, Three Way Crossover Study Comparing Two Different Sublingual Cannabis Based Medicine Extracts With Placebo, in Patients With Chronic Pain Due to Brachial Plexus Injury. Completed NCT01606189 Phase 3 GW-1000-02;GW-2000-02;Placebo
25 Nabilone for Cannabis Dependence: A Pilot Study Completed NCT01347762 Phase 2, Phase 3 Nabilone;Placebo
26 Reaching and Motivating Change in Teen Marijuana Smokers Completed NCT01109563 Phase 3
27 Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study Recruiting NCT03485274 Phase 2, Phase 3 Vortioxetine
28 N-Acetylcysteine for Youth Cannabis Use Disorder Recruiting NCT03055377 Phase 2, Phase 3 N-acetyl cysteine;Placebo oral capsule
29 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder Recruiting NCT02803229 Phase 2, Phase 3 Adderall-XR;Matched placebo
30 Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Recruiting NCT03481959 Phase 3 Methylphenidate
31 Vaping THC From Electronic Cigarettes: a Novel Evaluation of Intake and Pharmacokinetics Recruiting NCT02955329 Phase 3 Nicotine only;THC only;Nicotine and THC
32 Safety and Efficacy of PPP011-kit for Improving Health Related Quality of Life in Patients With Advanced Cancer and Uncontrolled Symptoms: A Randomized, Double-blind, Placebo-Controlled, Parallel Group Study Not yet recruiting NCT04001010 Phase 3 PPP011;Placebo
33 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study to Investigate the Safety and Efficacy of Cannabis Oil in Maintenance Hemodialysis Patients With Protein-energy Wasting Not yet recruiting NCT03664141 Phase 3 Cannabis oil;Placebo/ Regular Oil
34 Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study- Terminated NCT01071135 Phase 3 Quetiapine XR
35 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Terminated NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
36 Integration of Internet-facilitated Screening, Brief Intervention, Referral to Treatment (iSBIRT) for Teen Drug Use Into a Pediatric Network Withdrawn NCT01454206 Phase 2, Phase 3
37 Randomized and Double-blind Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
38 Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction Unknown status NCT00543036 Phase 1, Phase 2
39 CANDIS -Targeted Treatment for Cannabis Disorders Unknown status NCT00252980 Phase 2
40 Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study Unknown status NCT02083874 Phase 2 CBD
41 A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
42 The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer Unknown status NCT03245658 Phase 2 THC and CBD Mixture
43 Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents Completed NCT01110434 Phase 2 Topiramate;Placebo
44 Reaching and Motivating Change in Teen Marijuana Smokers Completed NCT00350285 Phase 2
45 Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment Completed NCT00142961 Phase 2 Atomoxetine
46 A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence Completed NCT00360191 Phase 2 Buspirone
47 A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction Completed NCT00217971 Phase 2 Dronabinol;Placebo
48 The Effect of Prescription Medications in Marijuana Users Completed NCT00893074 Phase 1, Phase 2 Dronabinol 30mg/day;Dronabinol 60mg/day;Dronabinol 120mg/day;Placebo
49 Gabapentin for Cannabis Withdrawal and Use Completed NCT00395044 Phase 2 Placebo;Gabapentin
50 Effects of Bupropion on Marijuana Withdrawal Symptoms Completed NCT00142870 Phase 2 Bupropion

Search NIH Clinical Center for Cannabis Abuse

Genetic Tests for Cannabis Abuse

Anatomical Context for Cannabis Abuse

MalaCards organs/tissues related to Cannabis Abuse:

40
Brain, Testes, Eye, Lung, Cortex, Spinal Cord, Breast

Publications for Cannabis Abuse

Articles related to Cannabis Abuse:

(show top 50) (show all 714)
# Title Authors PMID Year
1
Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. 54 61
16540246 2006
2
Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. 54 61
15500971 2004
3
Systemic administration with tetrahydrocannabinol causes retinal damage in BALB/c mice. 61
31680560 2020
4
Probability and correlates of transition from cannabis use to DSM-5 cannabis use disorder: Results from a large-scale nationally representative study. 61
31916333 2020
5
Modeling the Comorbidity of Cannabis Abuse and Conduct Disorder/Conduct Problems from a Cognitive Neuroscience Perspective. 61
31608811 2020
6
Epileptic Spikes in EEG and Migraine Attacks in the Course of Cannabis Withdrawal: A Case Report. 61
31741395 2020
7
Rates, predictors and the impact of cannabis misuse on in-hospital outcomes among patients undergoing percutaneous coronary intervention (from the National Inpatient Sample). 61
31922638 2020
8
Influence of the type of childhood violence on cannabis abuse and dependence among adolescents: a systematic review and meta-analysis. 61
30627731 2020
9
[Cannabis, Cannabinoids and Cannabis Use Disorders]. 61
31847034 2019
10
Brain activation to cannabis- and alcohol-related words in alcohol use disorder. 61
31715379 2019
11
Older Adults Driving Under the Influence: Associations With Marijuana Use, Marijuana Use Disorder, and Risk Perceptions. 61
29199501 2019
12
Cannabis use disorder among people using cannabis daily/almost daily in the United States, 2002-2016. 61
31698323 2019
13
Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis. 61
31808250 2019
14
Analysis of cannabinoids in urine samples of short-term and long-term consumers of hemp seed products. 61
31670217 2019
15
The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes: cannabis may have a greater impact in non-tobacco smokers. 61
31743053 2019
16
Regular cannabis use, with and without tobacco co-use, is associated with respiratory disease. 61
31557578 2019
17
Affective and Substance Abuse Disorders Following Abortion by Pregnancy Intention in the United States: A Longitudinal Cohort Study. 61
31731786 2019
18
Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries: A Retrospective Cohort Analysis. 61
31789638 2019
19
Synergistic effects of marijuana abuse and HIV infection on neural activation during a cognitive interference task. 61
30239074 2019
20
Relationships between Problematic Cannabis Use and Risky Behaviors in Spanish Adolescents. 61
31438581 2019
21
Threat Responsiveness as a Function of Cannabis and Alcohol Use Disorder Severity. 61
31170004 2019
22
Cannabis Abuse and Elevated Risk of Myocardial Infarction in the Young: A Population-Based Study. 61
31378243 2019
23
Cannabis Smoking-induced Diffuse Alveolar Hemorrhage. 61
31511809 2019
24
Demographic, Cannabis Use, and Depressive Correlates of Cannabis Use Consequences in Regular Cannabis Users. 61
31016818 2019
25
Sexual orientation and mental health over the life course in a birth cohort. 61
31190681 2019
26
Neuregulin-1 is increased in schizophrenia patients with chronic cannabis abuse: Preliminary results. 61
30799217 2019
27
Schizophrenia, cannabis use and Catechol-O-Methyltransferase (COMT): Modeling the interplay on cognition. 61
30790675 2019
28
Cannabis abuse and dependence in kidney transplant candidates. 61
31003856 2019
29
Marijuana Induced Sick Sinus Syndrome: A Case Report. 61
31227686 2019
30
Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. 61
31092662 2019
31
Cannabis Abuse or Dependence During Pregnancy: A Population-Based Cohort Study on 12 Million Births. 61
30448107 2019
32
Trace Detection of Tetrahydrocannabinol in Body Fluid via Surface-Enhanced Raman Scattering and Principal Component Analysis. 61
30907578 2019
33
Marijuana smoking and markers of testicular function among men from a fertility centre. 61
30726923 2019
34
The relationship between motivations for cannabis consumption and problematic use. 61
31018002 2019
35
Differential dysfunctions related to alcohol and cannabis use disorder symptoms in reward and error-processing neuro-circuitries in adolescents. 61
30710868 2019
36
Context matters: Characteristics of solitary versus social cannabis use. 61
30779237 2019
37
Disappearance of Tramadol and THC-COOH in Hair After Discontinuation of Abuse. Two Different Profiles. 61
30715334 2019
38
[Risk factors for the development of schizophrenia]. 61
30802921 2019
39
Cannabinoids Identification in Lung Tissues of Young Cannabis Smokers Operated for Primary Spontaneous Pneumothorax and Correlation with Pathologic Findings. 61
31600764 2019
40
The epigenetic modulation of alcohol/ethanol and cannabis exposure/co-exposure during different stages. 61
30958117 2019
41
Posttraumatic Stress Disorder Is a Risk Factor for Multiple Addictions in Police Officers Hospitalized for Alcohol. 61
31117072 2019
42
Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse. 61
30572414 2019
43
Δ9-Tetrahydrocannabinol During Adolescence Attenuates Disruption of Dopamine Function Induced in Rats by Maternal Immune Activation. 61
31551729 2019
44
Cannabis users: Screen systematically, treat individually. A descriptive study of participants in a randomized trial in primary care. 61
31790425 2019
45
Longitudinal Alterations in Prefrontal Resting Brain Connectivity in Non-Treatment-Seeking Young Adults With Cannabis Use Disorder. 61
31404267 2019
46
Case-control study analysis of DRD2 gene polymorphisms in drug addicted patients. 61
30659563 2018
47
Overlap of heritable influences between cannabis use disorder, frequency of use and opportunity to use cannabis: trivariate twin modelling and implications for genetic design. 61
29530110 2018
48
Medical cannabis use in older patients: Update on medical knowledge. 61
30415756 2018
49
Potential of an Interactive Drug Prevention Mobile Phone App (Once Upon a High): Questionnaire Study Among Students. 61
30514697 2018
50
The relationship of IQ and emotional processing with insula volume in schizophrenia. 61
29954697 2018

Variations for Cannabis Abuse

Expression for Cannabis Abuse

Search GEO for disease gene expression data for Cannabis Abuse.

Pathways for Cannabis Abuse

Pathways related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 WASF2 WASF1 OPRM1 NRG1 NGF NAPEPLD
2
Show member pathways
13.32 OPRM1 HTR1A GPR55 GABRA2 DRD4 DRD2
3 12.19 OPRM1 NGF HTR1A COMT CNR1
4
Show member pathways
12.1 WASF2 WASF1 NRG1 NGF BDNF
5
Show member pathways
11.95 OPRM1 NAPEPLD MGLL GABRA2 FAAH CNR1
6
Show member pathways
11.69 HTR1A DRD4 DRD2
7 11.64 GPR55 DRD4 CNR1
8 11.2 NGF DRD2 BDNF
9 10.78 FAAH CNR2 CNR1
10
Show member pathways
10.29 HTR1A DRD4 DRD2 COMT

GO Terms for Cannabis Abuse

Cellular components related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 OPRM1 NRG1 HTR1A GPR55 GABRA2 DRD4
2 cell projection GO:0042995 9.88 WASF2 SPATA6 OPRM1 GABRA2 CNR2 CNR1
3 axon GO:0030424 9.56 OPRM1 NRG1 NGF GABRA2 DRD2 COMT
4 integral component of presynaptic membrane GO:0099056 9.5 OPRM1 DRD2 CNR1
5 GABA-ergic synapse GO:0098982 9.46 NRG1 GABRA2 DRD2 CNR1
6 SCAR complex GO:0031209 9.37 WASF2 WASF1
7 dendrite GO:0030425 9.28 OPRM1 NGF HTR1A GABRA2 DRD4 DRD2

Biological processes related to Cannabis Abuse according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.19 OPRM1 HTR1A GPR55 GABRA2 DRD4 DRD2
2 G protein-coupled receptor signaling pathway GO:0007186 10.14 OPRM1 HTR1A GPR55 DRD4 DRD2 CNR2
3 response to lipopolysaccharide GO:0032496 9.87 OPRM1 COMT CNR2 CNR1
4 response to ethanol GO:0045471 9.83 OPRM1 DRD2 CNR1
5 locomotory behavior GO:0007626 9.81 OPRM1 NRG1 DRD2
6 memory GO:0007613 9.8 NGF CNR1 BDNF
7 modulation of chemical synaptic transmission GO:0050804 9.8 NGF DRD2 BDNF
8 synapse assembly GO:0007416 9.77 NRG1 DRD2 BDNF
9 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.76 WASF2 DRD2 CNR1
10 sensory perception of pain GO:0019233 9.75 OPRM1 CNR2 CNR1
11 neurotrophin TRK receptor signaling pathway GO:0048011 9.67 NGF BDNF
12 dopamine receptor signaling pathway GO:0007212 9.67 DRD4 DRD2
13 behavioral response to cocaine GO:0048148 9.67 DRD4 DRD2
14 response to cocaine GO:0042220 9.67 OPRM1 DRD2 CNR1
15 synaptic transmission, dopaminergic GO:0001963 9.66 DRD4 DRD2
16 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 DRD4 DRD2
17 nerve development GO:0021675 9.65 NGF BDNF
18 regulation of synaptic transmission, GABAergic GO:0032228 9.65 DRD2 CNR1
19 negative regulation of nitric-oxide synthase activity GO:0051001 9.64 CNR2 CNR1
20 nerve growth factor signaling pathway GO:0038180 9.64 NGF BDNF
21 regulation of dopamine metabolic process GO:0042053 9.62 HTR1A DRD4
22 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD4 DRD2
23 positive regulation of collateral sprouting GO:0048672 9.61 NGF BDNF
24 response to amphetamine GO:0001975 9.61 DRD4 DRD2 CNR2
25 regulation of sensory perception of pain GO:0051930 9.58 OPRM1 MGLL COMT
26 monoacylglycerol catabolic process GO:0052651 9.56 MGLL FAAH
27 negative regulation of mast cell activation GO:0033004 9.55 CNR2 CNR1
28 response to morphine GO:0043278 9.54 OPRM1 DRD2 CNR1
29 negative regulation of action potential GO:0045759 9.52 CNR2 CNR1
30 negative regulation of dopamine secretion GO:0033602 9.51 DRD2 CNR1
31 peripheral nervous system development GO:0007422 9.5 NRG1 NGF BDNF
32 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD4 DRD2
33 response to histamine GO:0034776 9.46 DRD4 DRD2
34 behavioral response to ethanol GO:0048149 9.43 OPRM1 DRD4 DRD2
35 dopamine metabolic process GO:0042417 9.33 DRD4 DRD2 COMT
36 cannabinoid signaling pathway GO:0038171 9.13 GPR55 CNR2 CNR1
37 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.02 OPRM1 HTR1A DRD4 CNR2 CNR1

Molecular functions related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.5 DRD4 DRD2 CNR1
2 G protein-coupled receptor activity GO:0004930 9.5 OPRM1 HTR1A GPR55 DRD4 DRD2 CNR2
3 dopamine binding GO:0035240 9.4 DRD4 DRD2
4 acylglycerol lipase activity GO:0047372 9.37 MGLL FAAH
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD4 DRD2
6 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD4 DRD2
7 cannabinoid receptor activity GO:0004949 8.8 GPR55 CNR2 CNR1

Sources for Cannabis Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....